A real world study of Ranibizumab in patients with visual impairment from the french BOREAL cohort.

Trial Profile

A real world study of Ranibizumab in patients with visual impairment from the french BOREAL cohort.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2017 New trial record
    • 30 Aug 2017 Results (n=290) assessing BCVA in patients with visual impairment due to diabetic macular edema presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 30 Aug 2017 Results (n=419) assessing BCVA in patients with visual impairment due to macular edema presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top